Core Research

KPV Research Overview

KPV is the tripeptide Lys-Pro-Val. Its small size makes the identity look simple, but the literature includes free KPV, acetylated/amidated forms and engineered KPV delivery systems. A useful KPV research overview therefore has to distinguish the peptide being tested from the carrier or chemical modification around it. This page is for laboratory research context only, not human or veterinary use.

What is KPV?

KPV is the Lys-Pro-Val tripeptide derived from the C-terminal region of alpha-melanocyte-stimulating hormone. In research papers, the exact terminal form can matter. Free KPV, Ac-KPV-NH2, glycoalkylated analogues and carrier-conjugated KPV are not chemically identical and should not inherit one another’s results.

PepT1 uptake and inflammatory signalling

Dalmasso and colleagues studied KPV in human intestinal epithelial cells and T cells and in mouse colitis models. Uptake experiments supported transport through the di/tripeptide transporter PepT1. In stimulated cells, KPV was associated with reduced NF-κB and MAP-kinase signalling and reduced pro-inflammatory cytokine secretion under the reported conditions. PubMed.

PepT1 is a transport mechanism, not a synonym for a melanocortin receptor. The paper is useful because it links cellular uptake with downstream signalling measurements without requiring the assumption that KPV simply reproduces the receptor pharmacology of full-length alpha-MSH.

Delivery architecture changes the experiment

Hyaluronic-acid-functionalised nanoparticles

Xiao and colleagues loaded KPV into polymeric nanoparticles functionalised with hyaluronic acid and studied targeted delivery to colonic epithelial cells and macrophages. The formulation was then evaluated in a mouse colitis model. The carrier design was part of the experimental intervention: the result cannot be assigned to free KPV alone. PubMed.

Inflammation-responsive proKPV conjugates

In 2026, Cheng and colleagues reported an engineered self-immolative KPV conjugate designed to protect peptide material through the gastrointestinal environment and release KPV in response to inflammatory reactive oxygen species. In their mouse studies, the proKPV system increased colonic accumulation compared with free KPV and produced different model outcomes. PubMed.

This is evidence for an engineered conjugate and delivery platform. It is not evidence that a lyophilised free-peptide vial has the same oral stability, tissue distribution or exposure profile.

Skin-cell stress research

A 2025 study by Sung and colleagues examined KPV in human HaCaT keratinocytes challenged with fine particulate matter, with additional work in a three-dimensional skin model. The investigators reported changes in cell-viability measurements, IL-1β secretion, reactive-oxygen-species measurements and MAPK/NF-κB-related signalling. PubMed.

The useful interpretation is model-specific: KPV changed measured stress/inflammatory responses under a defined particulate challenge. It should not be rewritten as a general claim that a commercial KPV product protects human skin from pollution or has a cosmetic treatment effect.

A negative antimicrobial finding worth keeping

Songok and colleagues tested Ac-KPV-NH2 and glycoalkylated KPV analogues. Under the antimicrobial assay conditions they examined, they found no antimicrobial activity for the parent Ac-KPV-NH2 or the modified analogues. The glycoalkylated peptides did show increased stability toward proteolytic enzymes. PubMed.

This distinction is important: improved enzyme stability is not the same result as antimicrobial activity, and a negative result in defined assays should not be removed simply because other KPV papers report anti-inflammatory findings.

How to read KPV evidence

Evidence questionInterpretive boundary
Was the tested peptide free KPV or a terminally modified form?Terminal chemistry can change mass, charge and stability.
Was KPV carried in nanoparticles, hydrogel or a conjugate?The delivery system can contribute materially to exposure and outcomes.
Was the endpoint transport, signalling, cytokine release or tissue pathology?These are different measurements and should not be collapsed into one “effect”.
Was the experiment cellular or animal?Neither establishes a clinical effect in people.
Was a negative result reported?Contrary or null findings help define where a proposed activity does not reproduce.

KPV identity and batch documentation

For a supplied KPV material, the analytical record should state the peptide form it is actually testing. A reference molecular weight for one terminal form cannot authenticate another. Likewise, HPLC purity and mass-spectrometry identity answer different questions.

Use the CoA-reading guide, HPLC guide and mass-spectrometry guide when interpreting product documentation.

KPV in the Core Research catalogue

The KPV 10mg vial, KPV Refill 10mg and KPV 10mg Pen are separate presentations. A shared peptide name does not establish identical packaging, handling or finished-format evidence.

Research-use boundary

The studies above are cell, animal and formulation research. They do not establish comprehensive human safety, a dosing protocol or a therapeutic indication for Core Research KPV products. Materials are supplied for laboratory research use only, not for human or veterinary use.

References

  1. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. doi:10.1053/j.gastro.2007.10.026.
  2. Xiao B, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles. Mol Ther. 2017. doi:10.1016/j.ymthe.2016.11.020.
  3. Songok AC, et al. Structural modification of the tripeptide KPV by reductive glycoalkylation of the lysine residue. PLoS One. 2018. doi:10.1371/journal.pone.0199686.
  4. Sung J, et al. Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation. Tissue Cell. 2025. doi:10.1016/j.tice.2025.102837.
  5. Cheng J, et al. Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers. Sci Adv. 2026. doi:10.1126/sciadv.aea2989.